[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.
NCT ID: NCT00354094
Last Updated: 2007-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
600 participants
INTERVENTIONAL
2006-11-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[S,S]-Reboxetine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients at screening must have a score of \>/=40mm on the pain visual analogue scale.
Exclusion Criteria
* Patients with other severe pain, that may impair the self-assessment of pain due to postherpetic neuralgia (pain after shingles).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Greensboro, North Carolina, United States
Pfizer Investigational Site
Fargo, North Dakota, United States
Pfizer Investigational Site
Cumberland, Rhode Island, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Viña del Mar, Región de Valparaíso, Chile
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Split, , Croatia
Pfizer Investigational Site
Hyderabad, Andhra Pradhesh, India
Pfizer Investigational Site
Chandigarh, Punjab, India
Pfizer Investigational Site
Bangalore, , India
Pfizer Investigational Site
Chennai, , India
Pfizer Investigational Site
Hyderabad, , India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
Kaunas, , Lithuania
Pfizer Investigational Site
Klaipėda, , Lithuania
Pfizer Investigational Site
Panevezys, , Lithuania
Pfizer Investigational Site
Šiauliai, , Lithuania
Pfizer Investigational Site
Mérida, Yucatán, Mexico
Pfizer Investigational Site
Sopot, , Poland
Pfizer Investigational Site
Ourense, OURENSE, Spain
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Bexhill-on-Sea, East Sussex, United Kingdom
Pfizer Investigational Site
Addlestone, SURREY, United Kingdom
Pfizer Investigational Site
Alcester, , United Kingdom
Pfizer Investigational Site
East Sussex, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6061030
Identifier Type: -
Identifier Source: org_study_id